Treatment of bullous pemphigoid with adjuvant immunoadsorption: A case series - 16/10/14
Supported by the Schleswig-Holstein Cluster of Excellence in Inflammation Research (DFG EXC 306/2) and Fresenius Medical Care. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. |
|
Disclosure: Drs Zillikens and Schmidt attended a consensus meeting on the use of immunoadsorption in autoimmune blistering disorders sponsored by Fresenius Medical Care. Drs Kasperkiewicz, Zillikens, and Schmidt received honoraria from Miltenyi Biotec and/or Fresenius Medical Care. Dr Zillikens has a scientific cooperation with Miltenyi Biotec. Drs Zillikens and Schmidt have a scientific cooperation with Fresenius Medical Care. Drs Schulze, Meier, van Beek, and Nitschke have no conflicts of interest to declare. |
|
Drs Kasperkiewicz and Schulze contributed equally. |
Vol 71 - N° 5
P. 1018-1020 - novembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?